antifungal susceptibility – Page 9

Aspergillus Bronchitis at Localised Mucus Plug in an Immunocompetent Patient

mycolabadmin

A 55-year-old woman developed a rare fungal infection called Aspergillus bronchitis in a mucus plug within her lung over a 9-year period. Although she was otherwise healthy with a normal immune system, the fungus gradually grew and eventually caused serious bleeding in her lungs. Doctors treated the bleeding with artery embolization and then surgically removed the affected lung tissue. The fungus was identified as Aspergillus udagawae, a type that is harder to treat with standard antifungal medications.

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common due to new cancer treatments and other medical advances, while some fungal species are developing resistance to standard antifungal medications. The good news is that several new antifungal drugs are in development with better safety profiles and novel mechanisms to fight these infections. However, the field faces challenges including limited specialized mycologists and difficulty designing clinical trials to properly test new treatments.

Candidemia due to Candida lambica in a neutropenic oncology patient: A rare case report

mycolabadmin

A 56-year-old cancer patient developed a serious bloodstream infection caused by a rare yeast called Candida lambica despite taking antifungal medications. Doctors identified the infection using genetic sequencing and found that the organism was sensitive to a different antifungal drug called voriconazole. After switching medications and removing the patient’s central line, the infection cleared up. This case demonstrates the importance of accurately identifying fungal infections and testing which medications work best against them.

Inferring fungal growth rates from optical density data

mycolabadmin

Scientists have developed a new mathematical method that allows doctors and lab technicians to measure fungal growth rates more accurately using simple optical density measurements. This approach doesn’t require expensive equipment or specialized knowledge, making it accessible to regular medical labs. The method could help doctors better assess how well antifungal drugs are working and detect resistant infections earlier.

A Rare Case of Alternaria citri Keratitis Successfully Treated with Voriconazole

mycolabadmin

A 71-year-old woodworker developed a serious eye infection caused by a rare fungus called Alternaria citri that damaged his cornea. Doctors identified the fungus using genetic testing and treated it with the antifungal drug voriconazole combined with surgery. After one year, his vision improved and the infection did not return, marking the first documented case of this particular fungal infection in humans.

Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model

mycolabadmin

Researchers developed tiny nanoparticle carriers coated with a fungal enzyme that helps them cross the protective barrier around the brain. These particles were loaded with an antifungal drug to treat brain infections caused by Cryptococcus neoformans. In laboratory tests, the Mpr1-coated particles successfully penetrated the blood-brain barrier better than regular nanoparticles and were more effective at killing the fungal cells.

Deep Fungal Infection of the Skin with Two Rare Fungi in a Dog Being Treated with Immunosuppressant Therapy: A Case Report

mycolabadmin

A dog being treated for brain inflammation with immune-suppressing drugs developed a serious skin infection caused by two unusual fungi not previously reported together in veterinary medicine. The infection proved difficult to diagnose, requiring tissue samples and specialized laboratory testing to identify the fungi and determine which antifungal drugs would work best. Despite treatment with antifungal medications and reducing the immunosuppressive drugs, the infection did not improve and the dog’s underlying condition worsened, ultimately requiring euthanasia. This case shows the serious risks of fungal infections in animals on long-term immunosuppressive therapy and highlights the need for careful monitoring and early detection.

Shifting etiological agents of dermatophytosis: a molecular epidemiological study from Iran

mycolabadmin

Researchers in Iran studied fungal infections of the scalp and nails using modern DNA testing methods. They found that the main fungus causing scalp infections (T. tonsurans) remains the most common, but a new species (T. indotineae) is increasingly causing nail infections and is resistant to common antifungal medicines. The study shows that traditional identification methods often misidentify these fungi, highlighting the importance of molecular testing for accurate diagnosis and treatment.

Infection caused by a cryptic fungal species, Blastomyces gilchristii, in a tiger

mycolabadmin

A tiger at a veterinary hospital developed a serious fungal infection that affected its brain and lungs. Using advanced DNA sequencing technology, researchers identified the infection was caused by a previously unrecognized fungal species called Blastomyces gilchristii. This discovery was important because it showed that this dangerous fungus exists in areas where scientists previously thought it wasn’t found, and it highlights the importance of using modern genetic testing to identify unusual infections.

Simplicillium sinense sp. nov., a novel potential pathogen of tinea faciei

mycolabadmin

Researchers identified a new fungal species called Simplicillium sinense that caused a facial skin infection (tinea faciei) in a 46-year-old man with diabetes. The fungus was resistant to most common antifungal medications but responded well to terbinafine treatment. This is the first reported case of a Simplicillium infection causing facial ringworm, expanding our understanding of rare fungal pathogens.

Research Keyword: antifungal susceptibility